AU2011279555B2 - Diagnostic for colorectal cancer - Google Patents

Diagnostic for colorectal cancer Download PDF

Info

Publication number
AU2011279555B2
AU2011279555B2 AU2011279555A AU2011279555A AU2011279555B2 AU 2011279555 B2 AU2011279555 B2 AU 2011279555B2 AU 2011279555 A AU2011279555 A AU 2011279555A AU 2011279555 A AU2011279555 A AU 2011279555A AU 2011279555 B2 AU2011279555 B2 AU 2011279555B2
Authority
AU
Australia
Prior art keywords
biomarkers
colorectal cancer
level
m2pk
igfbp2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011279555A
Other languages
English (en)
Other versions
AU2011279555A1 (en
Inventor
Antony Wilks Burgess
Leah Jane Cosgrove
Edouard Collins Nice
Bruce Tabor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vision Tech Bio Pty Ltd
Original Assignee
Vision Tech Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903140A external-priority patent/AU2010903140A0/en
Application filed by Vision Tech Bio Pty Ltd filed Critical Vision Tech Bio Pty Ltd
Priority to AU2011279555A priority Critical patent/AU2011279555B2/en
Publication of AU2011279555A1 publication Critical patent/AU2011279555A1/en
Application granted granted Critical
Publication of AU2011279555B2 publication Critical patent/AU2011279555B2/en
Assigned to VISION TECH BIO PTY LTD reassignment VISION TECH BIO PTY LTD Request for Assignment Assignors: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2011279555A 2010-07-14 2011-07-14 Diagnostic for colorectal cancer Active AU2011279555B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011279555A AU2011279555B2 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010903140A AU2010903140A0 (en) 2010-07-14 Diagnostic for colorectal cancer
AU2010903140 2010-07-14
PCT/AU2011/000895 WO2012006681A1 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer
AU2011279555A AU2011279555B2 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Publications (2)

Publication Number Publication Date
AU2011279555A1 AU2011279555A1 (en) 2013-01-31
AU2011279555B2 true AU2011279555B2 (en) 2016-10-20

Family

ID=45468816

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011279555A Active AU2011279555B2 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Country Status (13)

Country Link
US (2) US20130345322A1 (cg-RX-API-DMAC10.html)
EP (2) EP2593795A4 (cg-RX-API-DMAC10.html)
JP (1) JP6061344B2 (cg-RX-API-DMAC10.html)
CN (2) CN105755112B (cg-RX-API-DMAC10.html)
AU (1) AU2011279555B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013000745B1 (cg-RX-API-DMAC10.html)
DK (1) DK2829881T3 (cg-RX-API-DMAC10.html)
ES (1) ES2653646T3 (cg-RX-API-DMAC10.html)
IN (1) IN2013CN01129A (cg-RX-API-DMAC10.html)
NO (1) NO2829881T3 (cg-RX-API-DMAC10.html)
PT (1) PT2829881T (cg-RX-API-DMAC10.html)
RU (1) RU2013103995A (cg-RX-API-DMAC10.html)
WO (1) WO2012006681A1 (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2829881T (pt) * 2010-07-14 2017-11-29 Commw Scient Ind Res Org Diagnóstico para cancro colo-rectal
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
SI2883057T1 (sl) 2012-08-09 2019-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Diagnostika srčnega popuščanja
GB201218341D0 (en) * 2012-10-12 2012-11-28 Orign Sciences Ltd Diagnostic method
US20170176441A1 (en) * 2014-03-28 2017-06-22 Applied Proteomics, Inc. Protein biomarker profiles for detecting colorectal tumors
RS58957B1 (sr) * 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CN106191215B (zh) 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
US10877024B2 (en) * 2015-05-12 2020-12-29 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
CN105219844B (zh) * 2015-06-08 2018-12-14 华夏京都医疗投资管理有限公司 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型
CN105021828B (zh) * 2015-07-20 2017-07-28 上海交通大学医学院附属新华医院 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后
CN105567846A (zh) * 2016-02-14 2016-05-11 上海交通大学医学院附属仁济医院 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用
JP6984862B2 (ja) * 2017-03-15 2021-12-22 国立大学法人金沢大学 血中ケモカインをマーカーとして用いた大腸癌の検出
CN107164535A (zh) * 2017-07-07 2017-09-15 沈阳宁沪科技有限公司 一种无创高通量甲基化结肠癌诊断、研究和治疗方法
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
US11103171B2 (en) * 2018-10-23 2021-08-31 BlackThor Therapeutics, Ine. Systems and methods for screening, diagnosing, and stratifying patients
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
JP2022522803A (ja) * 2019-03-01 2022-04-20 アドバンスド マーカー ディスカバリー エセ． エレ． 結腸直腸癌及び／又はその前癌段階の診断用タンパク質シグネチャー
JP7300660B2 (ja) * 2019-04-03 2023-06-30 京都府公立大学法人 大腸がんの検出方法
JP7032764B2 (ja) * 2019-04-03 2022-03-09 京都府公立大学法人 大腸がんの検出方法
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
WO2021097327A1 (en) * 2019-11-13 2021-05-20 University Of Virginia Patent Foundation Treatment of clostridium difficile infections
EP3835789A1 (en) 2019-12-13 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Biomarker panel for diagnosing colorectal cancer
WO2022130597A1 (ja) * 2020-12-18 2022-06-23 国立大学法人東北大学 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム
JP2024505333A (ja) * 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
EP4327100A4 (en) * 2021-04-20 2025-02-26 Vision Tech Bio Pty Ltd Biomarkers for colorectal cancer
US20250035631A1 (en) * 2021-08-11 2025-01-30 Vision Tech Bio Pty Ltd Method of detecting adenoma
WO2023128419A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용
WO2023128429A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 진행 선종의 선별 검사 방법 및 그 응용
CN114594259B (zh) * 2022-04-22 2022-09-13 北京易科拜德科技有限公司 一种新型的用于结直肠癌预后预测和诊断的模型及其应用
PL441319A1 (pl) * 2022-05-31 2023-12-04 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
CN116219007B (zh) * 2022-09-15 2026-06-05 绍兴积准生物科技有限公司 检测结直肠癌的生物标志物组及其应用
WO2026064804A1 (en) * 2024-09-23 2026-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for rapid intraoperative histopathologic diagnosis
WO2026068795A2 (en) 2024-09-30 2026-04-02 Roche Diagnostics International Ag Clec3b for assessing colorectal cancer (crc) or a precancerous condition thereof
WO2026068798A1 (en) 2024-09-30 2026-04-02 Roche Diagnostics International Ag Sox9 for assessing colorectal cancer (crc) or a precancerous condition thereof
WO2026068794A1 (en) 2024-09-30 2026-04-02 Roche Diagnostics International Ag Auto-antibodies to anpep for assessing colorectal cancer (crc) or a precancerous condition thereof
CN119688988A (zh) * 2024-11-25 2025-03-25 中国医学科学院肿瘤医院 Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用
CN121186364B (zh) * 2025-11-25 2026-04-14 长兴固容生物科技有限公司 一种用于胃癌筛查、诊断的标志物组及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008138522A1 (en) * 2007-05-10 2008-11-20 Roche Diagnostics Gmbh Use of timp-1 as a marker for colorectal cancer
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009037572A2 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
WO2010065567A2 (en) * 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2011090516A1 (en) * 2010-01-19 2011-07-28 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
BRPI0401830A (pt) 2004-05-25 2006-01-17 Bentonit Uniao Nordeste Sa Processo de produção de pós granulados secos
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
WO2008073660A1 (en) 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008100913A2 (en) 2007-02-12 2008-08-21 The Johns Hopkins University Early detection and prognosis of colon cancers
DK2472264T3 (en) * 2007-02-27 2016-02-29 Sentoclone Internat Ab Multiplekspåvisning of tumor cells using a panel of agents which bind to extracellular markers
WO2008116178A2 (en) * 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
US20090017463A1 (en) * 2007-07-10 2009-01-15 Vanderbilt University Methods for predicting prostate cancer recurrence
EP2271775A4 (en) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
US20100111969A1 (en) * 2008-10-31 2010-05-06 Apogenix Gmbh Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
US9354233B2 (en) * 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
PT2829881T (pt) * 2010-07-14 2017-11-29 Commw Scient Ind Res Org Diagnóstico para cancro colo-rectal

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008138522A1 (en) * 2007-05-10 2008-11-20 Roche Diagnostics Gmbh Use of timp-1 as a marker for colorectal cancer
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009037572A2 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
WO2010065567A2 (en) * 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2011090516A1 (en) * 2010-01-19 2011-07-28 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases

Also Published As

Publication number Publication date
CN105755112B (zh) 2019-06-07
EP2829881B1 (en) 2017-08-23
CN103140760B (zh) 2016-01-27
ES2653646T3 (es) 2018-02-08
NO2829881T3 (cg-RX-API-DMAC10.html) 2018-01-20
US20130345322A1 (en) 2013-12-26
EP2829881A3 (en) 2015-05-13
EP2829881A2 (en) 2015-01-28
WO2012006681A1 (en) 2012-01-19
RU2013103995A (ru) 2014-08-20
AU2011279555A1 (en) 2013-01-31
IN2013CN01129A (cg-RX-API-DMAC10.html) 2015-07-31
PT2829881T (pt) 2017-11-29
BR112013000745B1 (pt) 2021-02-02
US10877039B2 (en) 2020-12-29
JP6061344B2 (ja) 2017-01-18
EP2593795A4 (en) 2014-01-22
US20170205414A1 (en) 2017-07-20
CN105755112A (zh) 2016-07-13
DK2829881T3 (en) 2017-12-04
JP2013533977A (ja) 2013-08-29
BR112013000745A2 (pt) 2016-05-24
CN103140760A (zh) 2013-06-05
EP2593795A1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
US10877039B2 (en) Diagnostic for colorectal cancer
US9964542B2 (en) Bladder cancer detection composition, kit, and associated methods
US11208698B2 (en) Methods for detection of markers bladder cancer and inflammatory conditions of the bladder and treatment thereof
KR101566368B1 (ko) 암 검출을 위한 소변 유전자 발현 비율
CN115087869A (zh) 肺癌诊断用多种生物标志物及其用途
WO2008092094A2 (en) Method and materials for detection, diagnosis and management of ovarian cancer
CN113981097A (zh) 基于hspa4的生物标志物组及其在肝癌中的应用
CN113234830B (zh) 用于肺癌诊断的产品及用途
CN113981098A (zh) 用于肝癌诊断以及肝癌预后预测的生物标志物
US20250035631A1 (en) Method of detecting adenoma
CN113943815A (zh) 基于alk的生物标志物组及其应用
US20240393336A1 (en) Biomarkers for colorectal cancer
CN114107504A (zh) 用于检测肺癌及肺癌预后的生物标志物
CN112921094A (zh) 生物标志物用于评估早期结直肠癌
CN112795658A (zh) 早期结直肠癌的基于生物标志物的诊断
CN114015778A (zh) 预测肺癌的生物标志物组
CN112921095A (zh) 用于诊断早期结直肠癌的生物标志物及其应用
CN113025717A (zh) 早期结直肠癌的指示物
CN113061657A (zh) 诊断早期结直肠癌的产品及系统
CN112921096A (zh) 早期结直肠癌的预测

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ COSGROVE, LEAH JANE; TABOR, BRUCE; BURGESS, ANOTHONY WILKS AND NICE, EDOUARD COLLINS

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ COSGROVE, LEAH JANE; TABOR, BRUCE; BURGESS, ANTONY WILKS AND NICE, EDOUARD COLLINS

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VISION TECH BIO PTY LTD

Free format text: FORMER OWNER(S): COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION